|
MED27 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22044604925031E-16 |
| Normal-vs-Stage2 |
7.50560000000178E-05 |
| Normal-vs-Stage3 |
9.26119958499783E-10 |
| Normal-vs-Stage4 |
4.44250000000146E-05 |
| Stage1-vs-Stage2 |
7.585000E-01 |
| Stage1-vs-Stage3 |
6.557400E-01 |
| Stage1-vs-Stage4 |
6.220400E-01 |
| Stage2-vs-Stage3 |
9.762400E-01 |
| Stage2-vs-Stage4 |
5.650800E-01 |
| Stage3-vs-Stage4 |
5.007600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
5.52169999999963E-05 |
| Normal-vs-Asian |
2.07249999999437E-05 |
| Caucasian-vs-AfricanAmerican |
7.765400E-01 |
| Caucasian-vs-Asian |
8.691400E-01 |
| AfricanAmerican-vs-Asian |
8.948200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.99239563420429E-11 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
4.844200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62847513252018E-12 |
| Normal-vs-Age(41-60Yrs) |
1.68276503842435E-12 |
| Normal-vs-Age(61-80Yrs) |
3.48429999996736E-06 |
| Normal-vs-Age(81-100Yrs) |
1.775360E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.870800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.278000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.875800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.757200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.548600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.264000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.414200E-01 |
| Classical-VS-Follicular |
2.698200E-02 |
| Classical-VS-Other |
6.487200E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
8.084200E-01 |
| Tall-VS-Other |
8.793400E-01 |
| Tall-VS-Normal |
1.160190E-03 |
| Follicular-VS-Other |
7.830400E-01 |
| Follicular-VS-Normal |
1.9161099999998E-05 |
| Other-VS-Normal |
3.798300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.63042929052426E-14 |
| Normal-vs-N1 |
1.418830E-04 |
| N0-vs-N1 |
2.933200E-01 |
|
|
